We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., has appointed Dr. Richard Woodman as Chief Clinical Officer of its Oncology Business Group.